Information about Enfuvirtide
Liver safety of Enfuvirtide
Mechanism of action of Enfuvirtide
Enfuvirtide (en fue' vir tide) is relatively new antiretroviral drug that blocks the fusion of HIV to target cell, preventing viral entry and subsequent infection. Enfuvirtide is a 36 amino acid biomimetic peptide that resembles the HIV proteins that are responsible for the fusion of the virus to cell membranes and subsequent intracellular uptake. Enfuvirtide has both in vitro and in vivo activity against HIV, and several randomized controlled trials have shown that it leads to significant decline in HIV RNA levels and rises in peripheral [[CD4 T cell counts].
FDA approval information for Enfuvirtide
Enfuvirtide was approved for use in the United States in 2003, but it has had limited use, partially because it requires parenteral administration once or twice daily. Enfuvirtide is available in single use vials that contain 90 mg/mL after reconstitution under the brand name of Fuzeon. The recommended regimen for enfuvirtide is 90 mg subcutaneously twice daily in adults and 2 mg/kg in children ages 6 to 16. Enfuvirtide is recommended only in combination with other antiretroviral agents.
Side effects of Enfuvirtide
The only common side effects specifically linked to enfuvirtide have been injection site reactions (which can be troublesome) and eosinophilia. Regimens that include enfuvirtide have the potential to cause immune reconstitution syndrome, pneumonitis and severe hypersensivity reactions.
Drugs for HIV Infection, in the Subclass Antiretroviral Agents
- Nonnucleoside Reverse Transcriptase Inhibitors (HIV)
- Nucleoside Analogues (HIV)
- Protease Inhibitors (HIV)
HCV NS5A Inhibitors
HCV NS5B (Polymerase) Inhibitors
- Asunaprevir, Boceprevir, Glecaprevir, Grazoprevir, Paritaprevir, Simeprevir, Telaprevir, Voxilaprevir
Drugs for Herpes Virus Infections (HSV, CMV, others)
Drugs for Influenza